N4 PHARMA PLC — Director's Dealing 2014

Nov 25, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9543X

Verona Pharma PLC

25 November 2014

Verona Pharma plc

("Verona Pharma" or the "Company")

Director's Dealing

25 November 2014, Cardiff - Verona Pharma plc (AIM: VRP) announces that further to the announcement of 24 November 2014 detailing the appointment of Dr. David Ebsworth as Non-Executive Chairman of the Board of Directors with effect from 1 December 2014, the Company was informed today that Dr. Ebsworth has purchased 1,326,667 Ordinary Shares at a price of 1.4 pence per Ordinary Share.

As a result Dr Ebsworth is now beneficially interested in 1,326,667 ordinary shares, representing 0.13% of the issued share capital.

-Ends-

For further information please contact:

Verona Pharma plc	Tel: +44 (0) 20 7863 3300
Jan-Anders Karlsson, CEO
N+1 Singer	Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting	Tel: +44 (0)20 3727 1000
Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSXELFLZFFEFBZ